Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 1.9%

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s stock price was up 1.9% on Tuesday . The stock traded as high as $43.71 and last traded at $43.67. Approximately 27,646 shares changed hands during trading, a decline of 96% from the average daily volume of 752,133 shares. The stock had previously closed at $42.87.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on RARE shares. Wedbush reaffirmed a “neutral” rating and set a $48.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday. JPMorgan Chase & Co. lifted their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $107.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, April 5th. Canaccord Genuity Group lifted their target price on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the stock a “buy” rating in a research note on Wednesday, February 21st. Finally, Robert W. Baird lifted their target price on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 30th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.55.

Ultragenyx Pharmaceutical Trading Up 2.4 %

The stock has a market capitalization of $3.61 billion, a PE ratio of -5.19 and a beta of 0.65. The firm’s fifty day moving average is $48.22 and its 200-day moving average is $43.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.65) by $0.13. The firm had revenue of $127.39 million for the quarter, compared to analyst estimates of $119.38 million. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. Ultragenyx Pharmaceutical’s revenue was up 23.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.16) EPS. As a group, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.34 EPS for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 3,756 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $53.76, for a total transaction of $201,922.56. Following the sale, the executive vice president now directly owns 67,340 shares in the company, valued at $3,620,198.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 3,756 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $53.76, for a total transaction of $201,922.56. Following the sale, the executive vice president now directly owns 67,340 shares in the company, valued at $3,620,198.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John Richard Pinion sold 4,173 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $53.76, for a total transaction of $224,340.48. Following the sale, the insider now owns 89,268 shares in the company, valued at $4,799,047.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 31,974 shares of company stock worth $1,639,721. Company insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Ultragenyx Pharmaceutical by 19.9% in the fourth quarter. Vanguard Group Inc. now owns 8,673,432 shares of the biopharmaceutical company’s stock valued at $414,764,000 after purchasing an additional 1,440,264 shares in the last quarter. RTW Investments LP boosted its holdings in Ultragenyx Pharmaceutical by 27.4% in the fourth quarter. RTW Investments LP now owns 6,887,086 shares of the biopharmaceutical company’s stock valued at $329,340,000 after purchasing an additional 1,481,997 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Ultragenyx Pharmaceutical by 0.4% in the third quarter. Wellington Management Group LLP now owns 5,195,880 shares of the biopharmaceutical company’s stock valued at $185,233,000 after purchasing an additional 18,359 shares in the last quarter. BlackRock Inc. boosted its holdings in Ultragenyx Pharmaceutical by 4.0% in the second quarter. BlackRock Inc. now owns 5,067,027 shares of the biopharmaceutical company’s stock valued at $233,742,000 after purchasing an additional 193,671 shares in the last quarter. Finally, Sands Capital Management LLC boosted its holdings in Ultragenyx Pharmaceutical by 59.8% in the fourth quarter. Sands Capital Management LLC now owns 4,118,008 shares of the biopharmaceutical company’s stock valued at $196,923,000 after purchasing an additional 1,540,791 shares in the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.